Table 2.
Persistence with the index therapy and treatment modifications over the available follow-up duration
| All study GLP-1 RAs | exBID | exQW | DULAa | LIRA | LIXI | |
|---|---|---|---|---|---|---|
| Patients, n (%) | 7319 (100) | 92 (1.3) | 970 (13.3) | 3368 (46) | 2573 (35.2) | 316 (4.3) |
| Persistence, i.e., no discontinuation or switch of the index treatment | ||||||
| At 6 months, N (%) | 3984 (54.4) | 32 (34.8) | 451 (46.5) | 2084 (61.9) | 1291 (50.2) | 126 (39.9) |
| 95% CI of proportions | 53.3, 55.6 | 25.1, 44.5 | 43.4, 49.6 | 60.2, 63.5 | 48.2, 52.1 | 34.5, 45.3 |
| Persistence duration (days between the index date and end of follow-up) | ||||||
| Median (95% CI) | 238 (219, 293) | 73 (62, 140) | 150 (128, 176) | > 300a | 183 (167, 203) | 113 (88, 151) |
| 25th percentile | 62 | 62 | 58 | 86 | 63 | 51 |
| At least a first index treatment modification (including dose changes) | ||||||
| N (%) | 5073 (69.3) | 73 (79.3) | 610 (62.9) | 2231 (66.2) | 1886 (73.3) | 273 (86.4) |
| First treatment modification type, N (%)b | ||||||
| On-label up-titration | 305 (4.2) | 4 (4.3) | 0 (0.0) | 161 (4.8) | 140 (5.4) | 0 (0.0) |
| Off-label up-titration | 178 (2.4) | 1 (1.1) | 0 (0.0) | 89 (2.6) | 57 (2.2) | 31 (9.8) |
| Down-titration | 791 (10.8) | 2 (2.2) | 0 (0.0) | 531 (15.8) | 214 (8.3) | 44 (13.9) |
| Augmentation | 437 (6.0) | 5 (5.4) | 57 (5.9) | 197 (5.8) | 162 (6.3) | 16 (5.1) |
| Discontinuation | 2956 (40.4) | 55 (59.8) | 497 (51.2) | 1086 (32.2) | 1164 (45.2) | 154 (48.7) |
| Switch | 406 (5.5) | 6 (6.5) | 56 (5.8) | 167 (5.0) | 149 (5.8) | 28 (8.9) |
| Up-titration at any time by type, N (%)c | ||||||
| On-label up-titration | 340 (4.6) | 5 (5.4) | 0 (0.0) | 178 (5.3) | 157 (6.1) | 0 (0.0) |
| Off-label up-titration | 247 (3.4) | 1 (1.1) | 0 (0.0) | 126 (3.7) | 81 (3.1) | 39 (12.3) |
exBID exenatide twice daily, exQW exenatide once weekly, DULA dulaglutide, LIRA liraglutide, LIXI lixisenatide
aMedian persistence days for this cohort could not be calculated as more than 50% of the patients, over the entire follow-up, remained persistent
bPercentages are calculated over the total number of patients, overall and within each treatment cohorts
cUp-titration at any time was defined as any two consecutive prescriptions exceeding the index dose